The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
暂无分享,去创建一个
William C. Olson | N. Schülke | Paul J Maddon | W. Olson | W. Heston | D. Ma | Paul J. Maddon | Dangshe Ma | O. Varlamova | G. Donovan | J. Gardner | D. Morrissey | Robert R. Arrigale | C. Zhan | A. Chodera | K. G. Surowitz | Kenneth G. Surowitz | Norbert Schülke | Olga A. Varlamova | Gerald P. Donovan | Jason P Gardner | Donna M. Morrissey | Cenchen Zhan | Amy J. Chodera | Warren D. W. Heston | P. Maddon
[1] Min Lu,et al. Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein , 2002, Journal of Virology.
[2] George L. Wright,et al. Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.
[3] J. Mendelsohn. Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Bittner,et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.
[5] William C. Olson,et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.
[6] Lesley Seymour,et al. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. , 2003, The Lancet. Oncology.
[7] V. Reuter,et al. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. , 2001, Urology.
[8] B. Suffoletto,et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] Jeffrey A. Magee,et al. Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.
[11] J. Neefs,et al. Isolation and Expression of Novel Human Glutamate Carboxypeptidases with N-Acetylated α-Linked Acidic Dipeptidase and Dipeptidyl Peptidase IV Activity* , 1999, The Journal of Biological Chemistry.
[12] V. Reuter,et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.
[13] M. Morrow,et al. Chemoprevention of breast cancer: a model for change. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] F. Tortella,et al. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury , 1999, Nature Medicine.
[15] B. Slusher,et al. Characterization of the enzymatic activity of PSM: Comparison with brain NAALADase , 1999, The Prostate.
[16] J. Coyle,et al. Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. , 1999, Molecular pharmacology.
[17] H. Schägger,et al. Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. , 1994, Analytical biochemistry.
[18] M. Sliwkowski,et al. Perspectives on Anti-HER Monoclonal Antibodies , 2002, Oncology.
[19] N. Gironès,et al. Intermolecular disulfide bonds are not required for the expression of the dimeric state and functional activity of the transferrin receptor. , 1989, The EMBO journal.
[20] J. Coyle,et al. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Dhanasekaran,et al. Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.
[22] N. Rawlings,et al. Structure of membrane glutamate carboxypeptidase. , 1997, Biochimica et biophysica acta.
[23] Dennis R. Burton,et al. Why do we not have an HIV vaccine and how can we make one? , 1998, Nature Medicine.
[24] W. Fair,et al. Expression of the prostate-specific membrane antigen. , 1994, Cancer research.
[25] L. Freeman,et al. The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer. , 2002, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[26] V. Reuter,et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] W. Fair,et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. , 1993, Cancer research.
[28] J. Konvalinka,et al. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II , 2002, Journal of neurochemistry.
[29] J. Welsh,et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.
[30] B Chevrier,et al. The structure of the Aeromonas proteolytica aminopeptidase complexed with a hydroxamate inhibitor. Involvement in catalysis of Glu151 and two zinc ions of the co-catalytic unit. , 1996, European journal of biochemistry.
[31] H. Schägger,et al. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. , 1991, Analytical biochemistry.
[32] S. Harrison,et al. Crystal structure of the ectodomain of human transferrin receptor. , 1999, Science.
[33] W. Fair,et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. , 1995, Cancer research.
[34] M. Sadelain,et al. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? , 2001, Critical reviews in immunology.
[35] N. Bander,et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.
[36] Larry L. Green,et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice , 1997, Nature Genetics.